Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors

NCT00703911 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00703911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00703911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
March 31, 2008
Completion date
July 31, 2010
Enrollment
102 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a with inhibitors, haemophilia b with inhibitors